How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
News In Theranostics
Orano Med enters Next Phase of Collaboration with Roche
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
Thu Nov 20 2025
RADIOPHARMACEUTICAL RESEARCH AGREEMENT SIGNED WITH NORTHSTAR MEDICAL RADIOISOTOPES | NORTHSTAR MEDICAL RADIOISOTOPES, LLC
Wed Nov 12 2025
Next-Generation Targeted Alpha Therapy using Astatine Shows Promise in Thyroid Cancer Resistant to Conventional Treatment
Curium Establishes Legal Entity in China
Wed Dec 03 2025
UCLA Health launches Department of Nuclear Medicine and Theranostics
Tue Nov 18 2025
ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma
Mon Nov 17 2025
Novartis Opens New 10,000-Square-Foot Radioligand Therapy Manufacturing Facility in California
Wed Nov 12 2025
ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
WSAUA 2025: Impact of PSA Doubling Time and Absolute PSA on PSMA PET Positivity in Post-Prostatectomy Biochemical Recurrence
Wed Nov 12 2025
Rapid Growth of Radiopharmaceutical Therapy Highlights Need for Expertise
Tue Nov 11 2025
Clarity Pharmaceuticals’ copper theranostics platform delivers superior prostate cancer imaging results
Tue Oct 21 2025
Facet Life Sciences and XCancer Announce Strategic Partnership to Advance Theranostic Clinical Trials
Thu Nov 06 2025
Theranostics Market to Reach USD 12.5 Billion by 2034
Tue Nov 11 2025
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
Wed Nov 12 2025
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NA
Sat Oct 25 2025
Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer
Fri Oct 31 2025
SpectronRx begins commercial production of Actinium-225 for cancer therapies
Mon Nov 03 2025
ESMO: AlphaMedix™ phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
Mon Oct 20 2025
Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Wed Oct 15 2025
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
Sat Oct 18 2025
Clarity signs copper-67 Supply Agreement with Nusano
Thu Oct 16 2025
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
Mon Oct 20 2025
Co-PSMA trial achieves primary endpoint
Tue Oct 14 2025
NUCLIDIUM Presents Positive Phase I/II Results for First Copper-based PET Diagnostic in Neuroendocrine Tumors at EANM Congress 2025
Wed Oct 08 2025
High-Speed Whole-Body SPECT Tracks Tumor Evolution to Optimize Prostate Cancer Treatment
Mon Oct 13 2025
ESMO 2025: Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT + ARPI in Patients with PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition)
Tue Oct 21 2025
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
Thu Oct 02 2025
First-Line [177Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Mon Sep 29 2025
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
Thu Sep 25 2025
TerraPower, Evergy and the State of Kansas announce agreement to explore advanced nuclear energy deployment
Tue Sep 23 2025
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Mon Sep 15 2025
Orano Med achieves key milestone in French ATEF facility construction, an essential asset for large-scale production of innovative lead-212-based therapies
Fri Sep 12 2025
Clarity confirms US-based manufacturing in response to newly announced tariff on pharmaceuticals
Fri Sep 26 2025
New PET Tracer Enables Same-Day Imaging of Triple-Negative Breast and Urothelial Cancers
Sat Sep 20 2025
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Thu Sep 11 2025
ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001
Tue Sep 09 2025
Astatine-211—Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications
Mon Sep 01 2025
Radiopharmaceutical production gets boost from radium transfers to U.S.
Fri Aug 22 2025
Telix and FDA Agree on Resubmission Pathway for TLX101-CDx (Pixclara®) U.S. NDA
Tue Sep 09 2025
New Targeted Radiation Therapy Shows Near-Complete Response in Rare Sarcoma Patients
Wed Sep 17 2025
New Radiotheranostic Targets Identified for Diagnosis and Treatment of Endometrial Cancer
Thu Sep 04 2025
Lesion Analysis of 18F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma
Thu Sep 04 2025
Prediction of TP53 mutations across female reproductive system pan-cancers using deep multimodal PET/CT radiogenomics
Sun Aug 31 2025
PSMA PET/CT prior to salvage radiotherapy improves overall survival for prostate cancer patients: Real-world data from an entire country
Wed Aug 13 2025
Asta Bio and Alpha Nuclide Collaborate to Advance Preclinical and Clinical Development of 211-Astatine Targeted Radiotherapies in China
Fri Aug 15 2025
Enhanced activity localization and microscale dosimetry in alpha-emitter radiopharmaceutical therapy using integrated autoradiography and histological imaging
Thu Aug 14 2025
Catalyst MedTech launches nuclear medicine tech training program
Tue Aug 12 2025
PSMA PET/CT Facilitates Better Long-Term Survival Rates After Salvage Radiotherapy for Recurrent PCa
Wed Aug 13 2025
Mayo Clinic treats first person in the US with a novel radiopharmaceutical therapy for breast cancer
Fri Aug 01 2025
FDA accepts Lantheus’ NDA for new Pylarify formulation
Wed Aug 06 2025
Novel Radioimmunotherapy Eradicates Cancer Stem Cells in Ovarian Cancer Model
Thu Jul 24 2025
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
Tue Aug 05 2025
From CAR-T to RLT: Enhancing Precision Oncology with ARTBIO’s Radioligands
Tue Aug 05 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, o
Tue Aug 05 2025
Francesco Massari: The Prognostic Role of 68Ga-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer
Tue Aug 05 2025
Mayo Clinic treats first person in the US with a novel radiopharmaceutical therapy for breast cancer
Fri Aug 01 2025
Production and purification of research scale 161Tb using cation-exchange semi-preparative HPLC for radiopharmaceutical applications
Tue Apr 22 2025
SNMMI 2025: Head-to-Head Comparison of mpMRI, PSMA, and GRPR PET/CT for Local Staging of Primary Prostate Cancer: Results from a Prospective, Single-Arm, Single-Center Multimodal Imaging Tria
Nucleotron MIT and bioaccess® Launch Synapse Latam to Revolutionize Theranostics and Clinical Research Across Latin America
Sat Jul 19 2025
Targeting Glioblastoma with Precision: The Promise of Lutetium-177 ITM-31
Thu Jul 10 2025
SNMMI 2025: STARLiT: Stereotactic Body Radiotherapy and 177Lu PSMA-617 in Locally Advanced Prostate Cancer
Thu Jul 24 2025
Improving Access to Nuclear Medicine: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
Mon Jun 30 2025
Groundbreaking Cancer Therapy Clinical Trial with U.S. Department of Energy’s Accelerator-Produced Actinium-225 Set to Begin this Summer
Wed Jun 18 2025
Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals
Mon Jun 30 2025
Ratio Therapeutics secures isotope supply deal with Nusano for radiopharmaceutical development
Mon Jun 23 2025
PharmaLogic Completes Acquisition of Majority Stake in Agilera Pharma AS
Mon Jun 23 2025
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
Mon Jun 23 2025
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
Fri Jun 13 2025
SNMMI: PET imaging improves OMD detection in breast cancer patients
Mon Jun 23 2025
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
Wed Jun 25 2025
PanTera produces and supplies first Actinium-225 extracted from Thorium-229 in Belgium.
Thu Jun 12 2025
CLARITY PHARMACEUTICALS EXPANDS MANUFACTURING
Tue Jun 17 2025
Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
Wed Jun 25 2025
Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity
Tue Jun 10 2025
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Germany
Thu Jun 05 2025
Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma
Fri May 30 2025
Radiopharm’s HEAT Is On: First Patient Dosed in Pioneering HER2 Trial
Tue Jun 03 2025
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Mon Jun 02 2025
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
Fri May 30 2025
[68Ga]Ga-PSMA-11 PET/CT and [18F]Fluorocholine PET/CT in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial
Wed May 28 2025
New Combination Therapy Safe and Feasible for Neuroendocrine Tumor Patients
Wed May 21 2025
Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer
Thu May 01 2025
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
Mon May 19 2025
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
Mon May 12 2025
Ratio Therapeutics to construct radiopharmaceutical facility
Thu May 08 2025
Novel Radiolabeled Antibody Developed for Diagnosis and Treatment of Solid Tumors
Thu Apr 17 2025
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
Fri Apr 25 2025
SPECT/CT predicts overall survival in Pluvicto patients
Fri Apr 25 2025
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis
Mon Apr 28 2025
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
Thu Apr 17 2025
Novel Radiolabeled Antibody Developed for Diagnosis and Treatment of Solid Tumors
Thu Apr 17 2025
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Wed Apr 16 2025
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
Tue Apr 15 2025
AdvanCell proudly announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’
Fri Apr 11 2025
Curium enhances its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
Thu Apr 10 2025
PharmaLogic to Acquire Majority Stake in Agilera, Strengthening Global Expertise in Radiopharmaceutical Therapeutics
Wed Apr 09 2025
Akiram Therapeutics initiates Eurostars-funded collaboration to develop next-generation targeted alpha-therapeutics
Fri Apr 04 2025
FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
Fri Mar 28 2025
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Mon Mar 17 2025
Telix Adds Lead-212 Isotope Production Capability
Thu Mar 13 2025
Novel Radiotracer Identifies Biomarker for Triple-Negative Breast Cancer
Tue Mar 11 2025
177-Lutetium-PSMA vs Cabazitaxel: A Real-World mCRPC Study - Mike Wenzel
Mon Mar 03 2025
FES-PET shows promise staging patients with low-grade breast cancer
Tue Mar 04 2025
Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics
Thu Feb 27 2025
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
Wed Feb 26 2025
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
Wed Feb 26 2025
ASCO GU 2025: Seeing Is Believing: Radiographic Criteria to Assess Response
Thu Feb 13 2025
New PET tracer developed for breast cancer
Fri Feb 14 2025
Radiopharmaceutical Industry Trends Shaping 2025
Thu Feb 20 2025
JNM Publishes Procedure Standard/Practice Guideline for Fibroblast Activation Protein PET
Fri Jan 24 2025
Dosimetry key in Lu-177 cancer therapy
Wed Feb 05 2025
Longtime manufacturer ITM's lead radiotherapy outperforms standard of care in phase 3 neuroendocrine tumor trial
Tue Jan 28 2025
Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development
Thu Jan 16 2025
Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences
Tue Jan 28 2025
